515 related articles for article (PubMed ID: 28207836)
1. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
2. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
[TBL] [Abstract][Full Text] [Related]
3. Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice.
Winzell MS; Coghlan M; Leighton B; Frangioudakis G; Smith DM; Storlien LH; Ahrén B
Eur J Pharmacol; 2011 Aug; 663(1-3):80-6. PubMed ID: 21586282
[TBL] [Abstract][Full Text] [Related]
4. Allosteric activators of glucokinase: potential role in diabetes therapy.
Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
[TBL] [Abstract][Full Text] [Related]
5. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus.
Wang P; Liu H; Chen L; Duan Y; Chen Q; Xi S
J Diabetes Res; 2017; 2017():5812607. PubMed ID: 28191470
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice.
Gorman T; Hope DC; Brownlie R; Yu A; Gill D; Löfvenmark J; Wedin M; Mayers RM; Snaith MR; Smith DM
Diabetes Obes Metab; 2008 Sep; 10(10):885-97. PubMed ID: 18034843
[TBL] [Abstract][Full Text] [Related]
7. Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator.
Tsumura Y; Tsushima Y; Tamura A; Kato H; Kobayashi T
PLoS One; 2022; 17(3):e0265761. PubMed ID: 35312718
[TBL] [Abstract][Full Text] [Related]
8. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
[TBL] [Abstract][Full Text] [Related]
9.
Zambrana S; Lundqvist LCE; Mamani O; Catrina SB; Gonzales E; Östenson CG
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30037028
[No Abstract] [Full Text] [Related]
10. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
[TBL] [Abstract][Full Text] [Related]
11. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
Fyfe MC; White JR; Taylor A; Chatfield R; Wargent E; Printz RL; Sulpice T; McCormack JG; Procter MJ; Reynet C; Widdowson PS; Wong-Kai-In P
Diabetologia; 2007 Jun; 50(6):1277-87. PubMed ID: 17415548
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel glucokinase activator in rat and mouse models.
Lu M; Li P; Bandyopadhyay G; Lagakos W; Dewolf WE; Alford T; Chicarelli MJ; Williams L; Anderson DA; Baer BR; McVean M; Conn M; Véniant MM; Coward P
PLoS One; 2014; 9(2):e88431. PubMed ID: 24533087
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators.
Charaya N; Pandita D; Grewal AS; Lather V
Comput Biol Chem; 2018 Apr; 73():221-229. PubMed ID: 29518630
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
16. Regulation of liver glucokinase activity in rats with fructose-induced insulin resistance and impaired glucose and lipid metabolism.
Francini F; Castro MC; Gagliardino JJ; Massa ML
Can J Physiol Pharmacol; 2009 Sep; 87(9):702-10. PubMed ID: 19794521
[TBL] [Abstract][Full Text] [Related]
17. A Novel Acetyl-CoA Carboxylase 2 Selective Inhibitor Improves Whole-Body Insulin Resistance and Hyperglycemia in Diabetic Mice through Target-Dependent Pathways.
Takagi H; Tanimoto K; Shimazaki A; Tonomura Y; Momosaki S; Sakamoto S; Abe K; Notoya M; Yukioka H
J Pharmacol Exp Ther; 2020 Mar; 372(3):256-263. PubMed ID: 31900320
[TBL] [Abstract][Full Text] [Related]
18. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice.
Yang X; Yang J; Xu C; Huang M; Zhou Q; Lv J; Ma X; Ke C; Ye Y; Shu G; Zhao P
J Ethnopharmacol; 2015 Aug; 171():161-70. PubMed ID: 26051831
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hypoglycemic activity of total lignans from Fructus Arctii in the spontaneously diabetic Goto-Kakizaki rats.
Xu Z; Ju J; Wang K; Gu C; Feng Y
J Ethnopharmacol; 2014; 151(1):548-55. PubMed ID: 24269245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
